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Objectives: Market access entry agreements (MAA) are vital to access the Italian 
Market. MAAs, monitored by an AIFA registry, are divided into outcome based (cost-
sharing) and non-outcome based (risk-sharing and payment-by-results) agreements. 
The objective is to understand the MAA adoption, evolution and utilization vari-
ability among Therapeutic Areas. MethOds: The desk-based research was carried 
out by integrating different information sources, from AIFA and Gazzette Ufficiali 
to Regional HTA studies. Data was gathered for all the 82 products/indications 
belonging to an open registry signed up to a MAA since January 2006 up until April 
2015. Results: 59% products/indications have an outcome based MAA, 33% a 
non-outcome based and 1% both. A third of outcome based and a quarter of non-
outcome based MAAs have an additional volume agreement or spending cap. A 
maximum peak of 30 products/indications with MAA is recorded in 2014, compared 
to an annual average of 8. In 2006-2007 cost-sharing MAAs were predominantly 
adopted; in 2008-2011, outcome based MAAs were negotiated in approximately half 
of the cases (57%), becoming since 2012, the preferred conditional reimbursement 
scheme (78%). Focusing on Antineoplastic products, Leukemia drugs have only non-
outcome based agreements, Lymphoma, Melanoma, Breast, Colorectal and Ovary 
Cancer drugs have a prevalence of outcome based, whereas Renal Cell and Lung 
Cancer drugs have both. cOnclusiOns: Throughout the years there has been an 
increase in the adoption of a MAAs as they are considered a valuable strategy to 
manage payer budget impact and drug clinical benefit uncertainties. Since their 
introduction, the choice of MAA schemes utilized has witnessed an evolution, with 
an increasing preference for outcome based MAAs, though often applied together 
with additional financial saving schemes. Due to the model adoption variability of 
MAAs within the Therapeutic Areas, the study of their structure plays a key role in 
accessing the Italian Market.
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Objectives: We assessed NHS progress between 2004/5 and 2011/12 in reducing 
inequality in healthcare access and outcomes, with the aim of developing the first 
systematic approach to monitoring socioeconomic inequalities in NHS access and 
outcomes. MethOds: Indicators of healthcare access and outcomes at different 
stages of the patient pathway were constructed for all English small areas (2001 
LSOAs) from 2004/5 to 2011/12 using GMS, QOF, HES and ONS mortality and popula-
tion data – (1) GP supply: full time equivalent (FTE) GPs per 100,000 population, need-
weighted adjustment, (2) primary care quality: quality and outcomes framework 
performance, weighted by public health impact, (3) hospital waiting time: days from 
referral-to-treatment, allowing for patient-level casemix, (4) post-hospital mortality: 
12-month mortality after discharge, allowing for patient-level casemix, (5) amenable 
mortality: deaths from causes amenable to health care per 100,000 population, indi-
rectly age-sex-standardised. Slope and relative indices of inequality were calculated 
through small-area-level regression using all 32,482 Index of Multiple Deprivation 
2010 ranks, with regression-based tests of change over time. Results: Nationally, 
all unadjusted relative indices of inequality fell from 2004/5 to 2011/12 (with 95% 
CIs in brackets, where negative indices represent “pro-poor” inequality): (1) for GP 
supply from -2.2% [-2.9% to -1.6%] to -9.5% [-10.2% to -8.8%], (2) for primary care 
quality from 4.1% [3.6% to 4.6%] to 1.1% [0.6% to 1.6%], (3) for hospital waiting time 
from 3.2% [2% to 4.4%] to 2.7% [1.5% to 3.8%], (4) for post-hospital mortality from 
0.6% [2.3% to -1.2%] to -4.5% [-2.6% to -6.4%], and (5) for amenable mortality from 34% 
[36.5% to 31.4%] to 11.9% [14.6% to 9.2%]. cOnclusiOns: Socioeconomic inequal-
ity in healthcare access and outcomes in the English NHS reduced between 2004/5 
and 2011/12 in both relative and absolute terms on all our indicators (unadjusted), 
though all indicators except GP supply and post-hospital mortality continue to 
exhibit “pro-rich” inequality.
PHP222
METHODOLOgICAL gAPS In THE ASSESSMEnT Of THE UTILITY AnD BURDEn 
Of RISk MInIMISATIOn InTERvEnTIOnS
Bergamasco A1, Thurin N2, Salib M3, Yousif A4, Moride Y5
1YolaRx Consultants, Paris, France, 2Université de Bordeaux, Bordeaux, France, 3University 
of Montreal, Montreal, QC, Canada, 4YolaRx Consultants, Montreal, QC, Canada, 5Faculty of 
Pharmacy, Université de Montréal, Montreal, QC, Canada
Objectives: Risk minimization interventions (RMIs) implemented by drug manu-
facturers aim at optimizing the benefit-risk of medicines when important safety 
concerns related to product have been identified. In some situations, strict RMIs, 
such as controlled distribution programs or mandatory certification, may be 
required. Although aiming to improve patient’s safety, RMIs could be costly, time-
consuming, challenging and therefore, generate an undue burden on stakeholders. 
In some instances, regulatory agencies request that burden of RMIs be evaluated 
but no methodological guidance is available. The objective of the present study is 
to identify current methodologies used to evaluate the utility and burden associ-
ated with RMIs and to identify methodological gaps. MethOds: A non-systematic 
literature review was conducted using Medline and Embase in order to identify 
relevant publications that include an assessment of the utility and/or burden of 
RMI. Pragmatic searches using Google and Google Scholar search engines com-
pleted this analysis. Regulatory agencies websites were also consulted to identify 
potential existing guidelines related to the evaluation of the burden associated 
with RMIs. Results: A total of 362 relevant publications were identified in the 
literature. Among the methods used, surveys and focus groups appeared to be the 
most frequent as they allow to gather participants’ opinions providing a better 
understanding of the burden and potentially identifying optimization opportu-
nities. Mixed-method evaluations were also currently employed as they include 
guide their evaluation and use. While a need to stimulate pharmaceutical inno-
vation is widely recognized, cost containment is significant in decision-making. 
The objective of this research is to identify how members of the EU5 assess the 
innovative value of pharmaceuticals; understand the policies surrounding their 
market access and highlight potential drivers. MethOds: We assessed publicly 
available country guidelines and regulations to understand the evaluation and 
reimbursement process for innovative medicines. Findings were considered in 
light of definitions of innovation, market access conditions, reimbursement agree-
ments and sources of funding. Results: Across the EU5, definitions for innova-
tive medicines vary. In Italy, the approach involves an algorithm which forms the 
basis of the assessment and reimbursement process for innovative medicines at 
national level. In Spain, although innovation is considered alongside clinical and 
economic parameters in the evaluation of drugs, there are no special considera-
tions for reimbursement. France and Germany are both found to value innovation 
as a core criterion in the standard appraisal process with opportunities to facilitate 
market access in France and with prospects for price negotiations in Germany. In 
the UK, innovation is included as a modifying factor; however, the recently intro-
duced Early Access to Medicines Scheme, allows the UK to present a landscape 
facilitating the development of innovative medicines. cOnclusiOns: There are 
similarities and differences in the approaches used by the EU5 country members 
in their assessment and reimbursement of innovative medicines. While in some 
countries, innovative medicines benefit from lowered hurdles for market access; 
in other countries, innovation proves less impactful.
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Objectives: Patient Access Schemes (PAS) are agreed between pharmaceutical 
companies and the Department of Health (DoH, with input from National Institute 
of Health and Care Excellence [NICE]) that enable companies to offer discounts 
or rebates that reduce the cost of a drug. PAS proposals are made in the context 
of a NICE technology appraisal, with the aim of improving cost-effectiveness to 
enable a positive NICE recommendation. This research aims to systematically ana-
lyse all PASs for NICE- approved technologies with respect to the type of scheme 
agreed, indication, company and how these have varied over time. MethOds: 
Publically available technologies with approved PASs were identified from the NICE 
website and the date, treatment, indication, company, and type of scheme were 
extracted. Results: 49 PAS were identified involving 25 different companies. 51% 
(25/49) were for oncology medicines, 16% (8/49) rheumatology, 12% (6/49) ophthal-
mology, 6% (3/49) MS, and 14% (7/49) other. 76% (37/49) of PASs were simple dis-
counts, 14% (7/49) for free stock, 6% (3/49) dose caps, 2% (1/49) rebates, and 2% (1/49) 
response schemes. An average of 5.4 new PASs are agreed every year, but these have 
risen from 3 between 2007-2008 to 23 in 2013-2014. There is also a notable time trend 
in the type of PAS, with 97% (32/33) of PASs agreed since November 2011 being simple 
discounts versus only 31% (5/16) of those agreed beforehand. cOnclusiOns: PASs 
have been utilised by many pharmaceutical companies to help gain NICE approval 
primarily in oncology. Their utilisation has notably increased in recent years along-
side a very strong trend to almost exclusively be simple discount schemes, perhaps 
reflecting DoH aversion to managing more complex schemes. Nevertheless, the 
recent dose capping PAS agreed with GSK for Tafinlar in October 2014, illustrate that 
other types of schemes will still be considered acceptable by the DoH.
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Objectives: IVIgs are used off-label in a number of patients with rare diseases 
which is thought to be mostly responsible for their increasing use. We propose 
here to describe the market access framework set in the EU5 for IVIgs’ off-label use 
and determine if the level of evidence supporting off-label use influences its fund-
ing. MethOds: A literature review has been carried out in May 2015 using Pubmed 
and Datamonitor databases as well as websites of European Health authorities 
using the following terms: [off-label use OR unlicensed] AND [intravenous immuno-
globulin] AND [funding OR reimbursement]. Results: Despite its common practice, 
there is little regulation for off-label use and is generally funded when no approved 
therapeutic alternative exists. Schemes allowing pragmatic solutions for the funding 
of off-label use have been recently implemented in France through the granting of 
Temporary Recommendations for Use (RTUs), in Italy through pre-authorisation 
by AIFA (lista farmaci off label), in Germany with the implementation of BfARM 
off-label expert group. Funding through these schemes is granted if evidence of 
treatment success are shown and that there is no therapeutic alternatives. However, 
these schemes do not currently cover all drugs, including IVIgs. There is evidence 
of funding for IVIgs’ off-label use in Spain but no specific schemes are set up. In the 
UK, the Department of Health implemented a Demand Management Programme 
for IVIgs. Their indications are colour-coded according to their level of priority and 
funding is linked to the colour granted. We found that IVIg’s off-label use is funded if 
judged of a high priority. cOnclusiOns: IVIgs’ off-label use funding is not equally 
regarded in the EU5. Harmonisation of off-label use funding, dependant on the level 
of evidence available, may be considered in the future to ensure equal access to IVIg 
therapy amongst European patients.
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in studies from developed countries, while micronutrient deficiencies and critical 
illness were the most common conditions of interest in studies from developing 
countries. The most prevalent interventions identified were oral nutrition supple-
ments (12.0%) and parenteral nutrition (10.9%), while outcomes of interest were 
most frequently cost (53.3%), length of stay (47.8%), mortality (25.2%), or readmis-
sions (8.7%). cOnclusiOns: This literature review demonstrates that interest in 
the cost effectiveness of medical nutrition has increased in recent years with the 
majority of studies focusing on cost and length of stay in adults of all ages.
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Objectives: As one important goal of New Medical Reform in China, the equalization 
of basic medical and health services (BMHS) has drawn a lot of attention of policy-
makers and other stakeholders. The objectives were to evaluate implementation pro-
gress of the BMHS and compare the equalization differences among different regions 
in China. MethOds: Using literature analysis, brainstorming, TOPSIS and entropy-
weight method, we designed the evaluation indicator system which included 1 first 
class indicator (equalization index), 3 second class indicators (input index, output 
index and effect index) and 28 third class indicators. Based on above, we made the 
calculation and evaluation using the national macro statistical data. Results: 1) All 
the input index (0 to 91.18), output index (-4.14 to 35.56) and effect index (0 to 50.58) 
have been improved significantly from 2010 to 2012 in China (The year of 2010 was as 
a base value). 2) There were serious non-equalization problems in input, output and 
effect of BMHS between urban and rural areas in China. 3) The results evaluated from 
the perspective of eastern, middle and western regions showed that the equalization 
index value of eastern region was the biggest, and it was the smallest in the middle 
region in China. However, the gaps among these three regions were gradually nar-
rowing. cOnclusiOns: 1) Many reasons resulted to the non-equalization problems 
of BMHS in China. 2) It was the non-equalization of BMHS between urban and rural 
areas that was the most serious and urgent to be solved of in China. 3) In order to 
alleviate this problem, first, the binary household registration system between urban 
and rural areas should be integrated. Second, it should perfect the financing system 
reasonably and promote the development of the universal health insurance. Third, it 
should improve the efficiency of input and output of the health resources.
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Objectives: Social network analysis (SNA) has been globally used to successfully 
implement intervention programs, and track contagious diseases. Social capital 
and social support are also being recognized as predictors of improved health and 
well-being. However, not much data is available on the use of social networks in 
India. This systematic literature review was carried out to evaluate the utility of 
social networks as a change implementation tool in Indian healthcare. MethOds: 
Studies were retrieved from Embase, Pubmed and Cochrane databases, using 
relevant search strategies. Abstracts and posters from the relevant conferences 
were also hand searched. Included studies were primarily conducted in India, and 
reported the utility and impact of social networks, with a focus on SNA methods 
and metrics in various healthcare settings in India. Two researchers independently 
reviewed studies using the Cochrane methodology. Quality assessment of the 
included studies was conducted using the STROBE checklist. Results: In total, 
1100 potentially relevant studies were screened. Following screening of abstracts 
and full-text publications, about twenty primary publications (survey-based [focus 
groups, interviews], and community-based intervention studies) were included. 
SNA was primarily used in studying disease transmission networks such as HIV, 
and successful implementation of interventions towards neonatal mortality, and 
better maternal health. Further use included identification of knowledge dissemina-
tion networks in geriatric care, use of contraceptives, mental health, epilepsy, and 
autism. Detailed analyses of the findings from studies are still ongoing and will be 
presented in the poster. cOnclusiOns: Preliminary analysis shows that limited 
evidence exists on the use of SNA and impact of social networks on healthcare 
in India. It also highlights the disparity in the awareness among Indian health 
communities regarding the utility of social networks. For a country with divergent 
health systems and a huge rural population, the use of social networks may be very 
impactful in improving healthcare.
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Objectives: Value of information (VOI) analyses are performed to assess oppor-
tunity cost of uncertainty, usually from a payer or societal perspective. The aim of 
this study was to simulate the Expected Value of Sample Information (EVSI) from a 
manufacturer’s perspective and study the factors affecting the EVSI. MethOds: A 
model linking the probability of acceptance of a new treatment to the incremental 
cost effectiveness ratio (ICER) and uncertainty around it was assumed, based on 
acceptable ranges of ICER reported in the literature. Uncertainty was characterized 
as the probability of ICER being above the willingness-to-pay (WTP) threshold of 
£30,000/QALY. Different scenarios describing the sensitivity of the approval chance 
to the ICER and uncertainty were considered. The manufacturer was assumed to 
earn a revenue of £20 million over 10 years if the technology got accepted. EVSI 
was calculated for several values of prior ICER and uncertainty, using 10,000 simu-
several methodologies and usually combine qualitative and quantitative evalu-
ations. Indeed, documenting several aspects of the burden associated with RMI 
such as costs, time required to comply with specific requirements or healthcare 
professionals’ opinions is critical to obtain a comprehensive overview of the situa-
tion and develop targeted strategies aiming to enhance RMIs implementation and 
outcomes. cOnclusiOns: Several methodological gaps have been identified on 
the methods used to evaluate the utility and burden of RMIs.
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Objectives: SIGAPS is a bibliometric software tool developed in France to iden-
tify and analyse Medline-indexed publications produced by researchers. It takes 
account of the author’s ranking on the paper and the journal’s impact factor. Results 
are used to assign a financial value to hospital facilities. One of the objectives of 
the present survey was to assess impact on publishing. MethOds: The DIAzePAM 
(DIfficulties for Authors to Publish Articles in Medical journals) survey used the elec-
tronic address book of the bibliometric unit of the Paris Public Academic Hospitals 
Organisation (AP-HP), France to address a dedicated 39-item electronic question-
naire. Results: Between 28 May and 15 June 2015, 1191 subjects (female: 55%; 
< 45 years of age: 63%; doctors: 81%, pharmacists: 9%; hospital practitioners: 51%; 
academics: 25%) anonymously completed the questionnaire (response rate, 17%). 
80% of respondents had published at least 1 article in the previous 2 years (40% at 
least once as 1st author). The main reasons for publishing were scientific (96%) or 
reputation (76%); only 17% of respondents reported publishing to obtain SIGAPS 
points. Impact factor was the determining journal selection criterion (85%). 76% 
of respondents claimed not publishing enough. Major barriers to publication were 
lack of time to write (79%) or submit (27%), limited English (40%) or writing skills 
(32%), and difficulty starting writing (35%). 88% of respondents would appreciate 
support for English reediting (79%), critical reediting (63%), formatting (52%), writ-
ing (41%). This support was expected to save time and increase high impact factor 
journal submission and acceptance. 56% of respondents thought the financial value 
of SIGAPS should be used to pay for support. cOnclusiOns: Although impact 
factor remains decisive in choice of journal, French researchers do not publish to 
earn SIGAPS points, possibly because the financial value is not currently clearly 
allocated back to researchers.
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Objectives: To investigate the scientific research quality level of pharmacoeco-
nomics evaluation literature in China. MethOds: From 2009 to 2013, a total of 
1127 papers published in academic journals in China were evaluated in terms of 
an assessment framework of 5 first-class indexes and 24 second-class indexes. 
The score of 1 was given if the literature reported the information required by 
the index, while 0 was given without reporting. Quality of overall papers and 
different types of authors, with/without funding sources and evaluation tech-
nique type were assessed. Results: The average score for all sampled papers 
was only 0.347 (SD=0.476). The quality of papers with stating funding sources 
(P=0.006), applying cost-utility analysis (P=0.003) and multiple analysis techniques 
(P=0.061) received statistically significant higher scores. In the total sample, most 
literatures were about cost-effectiveness analysis (CEA). The problems of the low 
quality papers were mostly unclear interest conflict of authors, no representa-
tive samples, ambiguous criterion of comparators types, unreasonable cost cal-
culation, inaccurate explanation of outcomes and lack of uncertainty analysis, 
etc. cOnclusiOns: The scientific research quality level of pharmacoeconomics 
evaluation literature in China is low. It is necessary to further standardize and 
optimize pharmacoeconomics study in China in order to obtain reliable assess-
ment results for guiding practice.
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Objectives: Interest in medical nutrition health economics is growing as govern-
ments face continued pressure to contain healthcare costs. Medical nutrition is 
a cost-effective intervention for a variety of patient populations. This literature 
review summarizes global publication trends in medical nutrition health economics 
and identifies gaps in the body of evidence. MethOds: Relevant publications were 
identified using predetermined search criteria encompassing nutritional and health 
economic terms and multiple databases including Medline and Embase. Original 
studies which included subjects ≥ 18 years of age and published in English between 
January 2004 and October 2014 were included if they addressed both costs and 
clinical outcomes. Results: From 5,646 unique results, 274 studies met the inclu-
sion criteria. The number of publications increased over the inclusion period with 
studies conducted in developed countries exceeding those in developing countries 
by factors ranging from 2.7 in 2006 to 20 in 2010. The majority of studies were under-
taken in Europe (39.4%) and the United States/Canada (27.7%). Most of the studies 
(73.0%) included adults of all ages whereas a minority of studies (19.7%) included 
elderly (age 65+) only. Many studies were conducted in multiple settings, with the 
hospital (62.0%) and community (29.9%) being the most common. Malnutrition, 
surgery, and gastrointestinal disorders were the most common conditions of interest 
